Kwality Pharmaceuticals Share Price Hits 20% Upper Circuit After Q1 FY27 Earnings Results: Total Income Up 45.7% YoY

On August 10, 2026, Kwality Pharmaceuticals Limited released its unaudited consolidated financial results for the quarter ended June 30, 2026. 

The company reported a total income of ₹162.97 crore and net profit of ₹25.62 crore for the June 2026 quarter. 

Kwality Pharmaceuticals Q1 FY27 Earnings Results 

For the quarter ended June 30, 2026, the total income of Kwality Pharmaceuticals reached ₹162.97 crore. This represents a 45.7% increase compared to the ₹111.85 crore reported in the same quarter of the previous year.  

On a sequential basis, the total income rose by 3.0% from the ₹158.17 crore recorded in the quarter ended March 31, 2026. 

The company recorded a net profit of ₹25.62 crore for the June 2026 quarter. This figure reflects a 115.0% increase over the ₹11.92 crore profit reported for the June quarter of 2025.  

When compared to the March 2026 quarter profit of ₹25.31 crore, the company achieved a 1.2% growth. 

Annual Financial Data for FY26 

The consolidated financial summary for the full financial year 2026 is also available for review. For FY26, the total income for the company stood at ₹505.94 crore. During the same period, the net profit, or profit after tax, was recorded at ₹67.35 crore. 

Updated Corporate Guidance 

Kwality Pharmaceuticals Limited officially released its Q1FY27 investor presentation outlining upgraded performance parameters. Management raised its total fiscal year 2027 revenue guidance upward to a target of ₹700.0 crore. 

The updated guidance also projects a raised EBITDA target of ₹189.0 crore to ₹196.0 crore. Furthermore, expected profit after tax for the full fiscal year has been adjusted to exceed ₹109.0 crore. 

Long Term Targets 

Management outlined a strategic multi-year roadmap targeting a revenue milestone of INR 1000+ crore by fiscal year 2029. Profit margins are projected to expand by 300 basis points by fiscal year 2027. 

The targeted margin improvement is driven by massive capex execution, operational leverage, and a better product mix. These expectations exclude future upside contributions from upcoming specialized platforms. 

Capital Expenditure Additions 

The company is scaling up operations through a multi-year planned capital expenditure programs totaling approximately ₹195.0 crore. This includes a dedicated hormone manufacturing unit representing a planned capital layout of ₹65.0 crore. 

Half of the allocated hormone plant expenditure has already been successfully deployed by the company. The remaining civil works and infrastructure installations are scheduled for completion by November 2026. 

Dosage and Product Mix 

The company's diverse commercial baseline features a portfolio encompassing more than 1000 specialized formulations. Injectables comprise the largest share of operational value, accounting for 43% of total revenues. 

Tablets generate the second largest product contribution, securing 40% of the financial mix. Capsules, liquid externals, creams, ointments, dry syrups, and ophthalmic products constitute the remaining portion. 

Balance Sheet Ratios 

The company's historical financial balance sheet reveals that total asset volume expanded to ₹592.0 crore. Total equity attributable to shareholders reached ₹332.0 crore at the end of the fiscal year. 

The balance sheet is supported by low leverage, with a gross debt-to-equity ratio of 0.39. This leaves the pharmaceutical manufacturer with significant structural headroom to fund future capital expansions. 

Operating Efficiency Metrics 

The company recorded a massive improvement in its working capital requirements, optimization cycles, and asset turnover. Its cash conversion cycle shortened significantly from 297 days down to 161 days. 

This rapid acceleration was driven primarily by strict inventory management and normalized collection timelines. Meanwhile, return on equity expanded to 22.7% as capital productivity steadily optimized. 

Regulatory Infrastructure Scale 

The organization operates five manufacturing campuses, with four out of five units possessing official EU-GMP approvals. The centralized quality assurance architecture manages active commercial filings spanning more than 70 countries. 

The cumulative global regulatory filings increased from a baseline of 75 up to over 700 filings. The manufacturing infrastructure successfully cleared more than 20 independent international compliance audits. 

Growth Engines Pipeline 

The development engine is advancing its specialized biologics platform to address large regulated international demands. The platform possesses both drug substance and drug product formulation capabilities under WHO-GMP compliance. 

Commercialization of the company's first biological candidate, Erythropoietin, is slated for the next fiscal year. Additionally, generic variations targeting currently patented molecules are advancing through proof-of-concept stages. 

Read More: PB Fintech Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 36.9% YoY! 

Kwality Pharmaceuticals Share Price Performance 

As of August 10, 2026, at 1:26 PM, Kwality Pharmaceuticals share price on NSE was trading at ₹3,134.10, up by 20.00% from the previous closing price. 

Conclusion 

Kwality Pharmaceuticals reported a total income of ₹162.97 crore and a net profit of ₹25.62 crore for the June 2026 quarter, alongside full year 2026 figures of ₹505.94 crore income and ₹67.35 crore profit. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.